Desjardins Global Asset Management Inc. Acquires 181 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Desjardins Global Asset Management Inc. increased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,823 shares of the medical equipment provider’s stock after purchasing an additional 181 shares during the quarter. Desjardins Global Asset Management Inc.’s holdings in Zimmer Biomet were worth $2,047,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also bought and sold shares of the business. Vanguard Group Inc. increased its position in Zimmer Biomet by 19.0% during the first quarter. Vanguard Group Inc. now owns 23,102,761 shares of the medical equipment provider’s stock valued at $2,954,843,000 after acquiring an additional 3,695,510 shares during the last quarter. American Century Companies Inc. increased its position in shares of Zimmer Biomet by 21.2% during the 3rd quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock valued at $545,809,000 after purchasing an additional 852,186 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Zimmer Biomet by 2.3% in the 1st quarter. Geode Capital Management LLC now owns 4,315,167 shares of the medical equipment provider’s stock worth $556,244,000 after purchasing an additional 96,028 shares during the period. Morgan Stanley grew its position in Zimmer Biomet by 80.5% during the fourth quarter. Morgan Stanley now owns 3,102,429 shares of the medical equipment provider’s stock valued at $395,560,000 after buying an additional 1,384,068 shares during the period. Finally, Victory Capital Management Inc. increased its holdings in Zimmer Biomet by 4.9% during the third quarter. Victory Capital Management Inc. now owns 3,080,463 shares of the medical equipment provider’s stock valued at $345,690,000 after buying an additional 144,147 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Activity at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the sale, the vice president now owns 44,145 shares in the company, valued at approximately $5,677,929.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.70% of the stock is currently owned by insiders.

Zimmer Biomet Trading Down 1.6 %

ZBH stock opened at $122.07 on Wednesday. The firm has a market cap of $25.08 billion, a PE ratio of 24.96, a price-to-earnings-growth ratio of 2.28 and a beta of 1.01. The firm has a fifty day moving average price of $126.59 and a 200 day moving average price of $119.09. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $149.25.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The business had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.93 billion. During the same period last year, the company posted $1.88 EPS. The business’s revenue was up 6.3% on a year-over-year basis. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.79%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is currently 19.63%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ZBH shares. Royal Bank of Canada reissued an “outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 9th. Truist Financial raised their price objective on Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a research note on Friday, February 9th. Raymond James increased their target price on shares of Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Canaccord Genuity Group reaffirmed a “hold” rating and set a $130.00 price target on shares of Zimmer Biomet in a report on Friday, February 23rd. Finally, Barclays increased their price objective on shares of Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a research note on Monday, February 12th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $139.39.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.